Molecular Testing

Blueprint Medicines Presents Cost of Testing Poster

Blueprint Medicines presented a poster titled “The Cost Impact of Increased Molecular Testing Rates for the Treatment of Patients with Gastrointestinal Stromal Tumors” at the annual meeting of the AMCP.

By |2020-04-30T14:50:52-04:00April 30th, 2020|Mutational Testing, News, Patient Support|
Go to Top